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Summary
This study aims to explore if there is a change in nutritional risk and body mass index (BMI) in cancer patients during 
the systemic antineoplastic treatment. We retrospectively analyzed data collected from 216 cancer patients treated at the 
Department of Medical Oncology, University Hospital for tumors, Sestre Milosrdnice University Hospital Center, Zagreb, 
Croatia, with systemic antineoplastic therapy in the period from 05/2016 to 05/2018. In our study, we included both patients 
treated with systemic therapy for the first time and patients treated repeatedly (only patients who have had at least six 
months free period after the last treatment course were eligible). We included male and female patients with breast cancer, 
colorectal cancer, pancreatic cancer, and head and neck cancer. Around 75% of patients had metastatic disease. We analyzed 
data collected from Nutritional Risk Score-2002 (NRS-2002) screening and results of BMI, at first hospitalization, and after 
three months of systemic antineoplastic treatment. All patients at high nutritional risk (NRS 3-4) received the nutritional 
intervention, which included enteral nutritional supplement and education of patient and patient’s family about nutrition 
in oncological patients. We used the Wilcoxon test for the NRS score and t-test for a depended variable for BMI data. The 
initial average BMI of all patients was 26,45 kg/m². Of all screened patients, around 78% of them were at mild nutritional risk 
(NRS 1-2), while around 22% of them were at high nutritional risk (NRS 3-4). We recorded a statistically significant decrease 
both in NRS of the entire screened population of patients after three months of systemic antineoplastic treatment and after 
specific nutritional intervention in high-risk patients (most patients were at mild nutritional risk, while less than 8% of them 
were at high nutritional risk). There was no significant change in BMI in the observed period (average BMI was 26, 59 kg/
m²). It seems, systemic antineoplastic treatment, along with early nutritional intervention with enteral nutritive supplemen-
tation and education, can significantly contribute to the decrease of the nutritional risk.
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PROCJENA NUTRITIVNOG RIZIKA BOLESNIKA  
TIJEKOM SUSTAVNOG ANTINEOPLASTIČNOG LIJEČENJA
Sažetak
Cilj ovog rada je procijeniti promjena u nutritivnom riziku i indeksu tjelesne mase (ITM) onkoloških bolesnika tijekom 
sustavnog antineoplastičnog liječenja. Retrospektivno su analizirani podatci 216 bolesnika koji su od 05/2016 do 05/2018 li-
ječeni na Odjelu internističke onkologije Klinike za tumore, KBC Sestre milosrdnice, Zagreb, Hrvatska. Obuhvaćeni su bo-
lesnici po prvi put liječeni sustavnom antineoplastičnom terapijom i/ili koji u prethodnih 6 mjeseci nisu bili liječeni niti 
jednim vidom onkološkog liječenja. Zastupljeni su bolesnici obaju spolova, oboljeli od raka dojke, debelog i završnog crije-
va, gušterače te glave i vrata. Oko 75% bolesnika imalo je metastatsku bolest. Korišteni su rezultati NRS 2002 nutritivnog 
probira te rezultati indirektne procjene sastava tijela izračunom indeksa tjelesne mase (ITM) prilikom prve hospitalizacije te 
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nakon 3 mjeseca sustavnog antineoplastičnog liječenja. U svih bolesnika koji su bili u visokom nutritivnom riziku (NRS 3-4) 
je provedena nutritivna intervencija uvođenjem enteralne prehrane te edukacije bolesnika i obitelji o prehrani onkoloških 
bolesnika. Za statistički izračun su korišteni Wilcoxonov test za podatke o NRS-u te t-test za zavisne uzorke za podatke o 
ITM-u. Inicijalni prosječni ITM je na početku liječenja bio 26,45 kg/m². Inicijalnim nutritivnim probirom je utvrđen blagi 
nutritivni rizik (NRS 1-2) u oko 78% bolesnika, a oko 22% bolesnika je bilo u visokom nutritivnom riziku (NRS 3-4). Nakon 
3 mjeseca specifičnog onkološkog liječenja te provođenja nutritivne potpore u visoko ugroženih bolesnika, zabilježen je 
statistički značajan pad u nutritivnom riziku u ukupnoj ispitivanoj populaciji (većina bolesnika je bila u blagom nutritivnom 
riziku, dok je manje od 8% bolesnika bilo visokog nutritivnog rizika). U periodu praćenja nije bila zabilježena značajnija 
promjena u indeksu tjelesne mase (prosječni ITM je bio 26,59 kg/m²). Sustavno antineoplastično liječenje uz ranu nutritivnu 
intervenciju i edukaciju doprinosi smanjenju znakova bolesti i poboljšanju općeg stanja bolesnika te može značajno smanji-
ti nutritivni rizik.
KLJUČNE RIJEČI: nutritivni rizik (NR), indeks tjelesne mase (ITM), sustavno antineoplastično liječenje
INTRODUCTION
Weight loss, nutritional risk, and malnutri-
tion are frequent problems in cancer patients and 
is often the presenting sign of malignant disease. 
The physiological abnormalities due to the tumor 
(malabsorption, obstruction, diarrhea, vomiting), 
the host response to the tumor (causing anorexia 
and altered metabolism), and the side-effects of 
anticancer treatment can al cause weight reduc-
tion (1,2). Older publications reported that the fre-
quency of weight loss and malnutrition in cancer 
patients ranges from 31-87%, depending on the 
tumor site and stage (3). This data is consistent 
with newer publications in which nutrition risk 
prevalence ranges from 25% to over 70% based on 
nutritional assessment (4). According to the World 
Health Organization, in 2016. 39% of adults were 
overweight - 39% of men and 40% of women (5). 
Therefore it became challenging to identify mal-
nutrition in the overweight population and, con-
sequently, those in needing nutritional interven-
tion. Although unintentional weight loss is one of 
the first signs of malignancy, obese patients un-
derestimate the importance of that sign and usu-
ally do not report it to their physicians. Davidson 
et al. reported in their study 23 malnourished pa-
tients with normal or increased body mass index 
(BMI), which suggests that BMI and self-reporting 
of symptoms are not reliable measures for identi-
fying all patients at risk of malnutrition or with 
poor nutritional status (6).
Specific oncological treatment and cancer it-
self, cause metabolic and physiological alterations 
that affect the nutritional status of patients (7). Pa-
tients usually report chemotherapy-induced nau-
sea and vomiting, dysgeusia, diarrhea, or consti-
pation as a common side - effects of systemic anti-
cancer treatment, which also has an impact of 
deficient alimentation and malnutrition. Adverse 
outcomes such as increased morbidity, poor prog-
nosis, intolerance of treatment, and a decrease in 
quality of life can all be exacerbated by malnutri-
tion. This study aims to explore the change in nu-
tritional risk and body mass index (BMI) in cancer 
patients during the systemic antineoplastic treat-
ment.
MATERIAL AND METHODS
We retrospectively analyzed data collected 
from 216 cancer patients who were treated at the 
Department of Medical Oncology with systemic 
antineoplastic therapy in the period from 05/2016 
to 05/2018. In our study, we included both patients 
treated with systemic therapy for the first time and 
patients treated repeatedly (only patients who 
have had at least six months free period after the 
last treatment course were eligible). We included 
male and female patients with breast cancer, 
colorectal cancer, pancreatic cancer, and head and 
neck cancer. For nutritional assessment, we used 
the validated NRS-2002 screening tool on the first 
day of each hospitalization. It consists of an initial 
assessment that analyzed body mass index (BMI), 
history of weight loss in the last three months, 
changes in food intake, and severity of the under-
lying disease. We continue the assessment if there 
are one or more affirmative answers with final 
screening that analyzes the nutritional status and 
severity of disease (8). BMI was calculated as mea-
sured weight in kilograms and height in meters on 
the first day of hospitalization (BMI=kg/m 2). We 
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calculated the BMI on the first day of each subse-
quent hospitalization. According to BMI, patients 
were categorized as underweight (BMI <18,5), nor-
mal weight (BMI 18,5- 24,9), overweight (BMI 25-
29,9) and obese (BMI >30) (9). We analyzed data 
collected from NRS-2002 screening and results of 
BMI, at first hospitalization, and after three months 
of systemic antineoplastic treatment. All patients 
at high nutritional risk (NRS 3-4) received the nu-
tritional intervention, which included enteral nu-
tritional supplement and education of patient and 
patient’s family about nutrition.
Statistical analysis was based on the Wilcox-
on test for the NRS score and Student’s t-test for a 
depended variable for BMI data.
RESULTS
The majority of our 216 patients in the study, 
74.5% of them, were in the metastatic stage of the 
disease. Most of the patients had colorectal cancer 
Table 1.
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Abbreviations: BC - breast cancer; CRC - colorectal cancer; HNC - head and 
neck cancer; PC - pancreatic cancer
Table 2.
DESCRIPTIVE STATISTICS OF ANALYSED BMI AND NRS
N Mean SD Minimum Maximum
Percentiles
P value
25th 50th (Median) 75th
BMI (initially) 216 26,45 4,22 15,03 38,30 23,33 26,24 29,15
0,218
BMI (after 3 months) 216 26,59 4,12 15,82 38,05 23,68 26,35 29,55
NRS (initially) 216 1,83 0,92 1,00 4,00 1,00 2,00 2,00
<0,001
NRS (after 3 months) 216 1,36 0,67 1,00 4,00 1,00 1,00 2,00
Abbreviations: BMI- body mass index; NRS: nutritional risk score
Figure 1. Statistically significant decrease in nutritional risk 
score during an observed period
(around 63%), followed by breast cancer (approxi-
mately 28%). The initial average BMI of all pa-
tients was 26.45 kg/m². Of all screened patients, 
around 78% were at mild nutritional risk (NRS 
1-2), while about 22% of them were at high nutri-
tional risk (NRS 3-4) at the beginning of systemic 
antineoplastic treatment. Table 1 shows the gen-
eral characteristics of the studied sample. We re-
corded a statistically significant decrease in NRS 
of the entire screened population of patients after 
three months of systemic antineoplastic treatment 
and after specific nutritional intervention in high-
risk patients (most patients were at mild nutrition-
al risk, while less than 8% of them were at high 
nutritional risk) (Figure 1). There was no signifi-
cant change in BMI in the observed period (aver-




Our study showed that nutritional risk is still 
highly prevalent in oncological patients despite 
the multidisciplinary oncological treatments. The 
nutritional risk in the metastatic disease correlates 
with the burden of the disease and the number of 
comorbidities (10). Hebutern and al. stressed the 
importance of nutritional treatment in the overall 
treatment strategy (11). The general population is 
overweight, which is consistent with mean BMI in 
our study, and three month period is too short to 
follow up with a significant change in BMI. Our 
results of a decrease in NRS during systemic treat-
ment in three months period due to nutritional 
intervention is consistent with one recent study of 
Matelaro and al. (12). They also pointed out the 
importance of awareness of potential nutritional 
risk in cancer patients and value that dietary/nu-
tritional measures from the start of treatment aim 
to improve the nutritional status or even prevent 
its deterioration. Early nutritional intervention 
with enteral nutritive supplementation and edu-
cation of patients and their families about dietary 
needs and the importance of nutritional support 
significantly contribute to decreasing the nutri-
tional risk.
CONCLUSION
Nutritional assessment and early nutritional 
intervention should be incorporated into the ther-
apy plan for each cancer patient from the begin-
ning since it improves cancer therapy tolerance 
and the quality of life. Existing nutritional assess-
ment tools recognize patients at nutritional risk. 
The importance of continuous nutritional inter-
ventions throughout the care of oncology patients 
needs to be recognized by all concerned with ma-
lignant disease management.
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